![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, February 15, 2021 3:02:19 PM
The rather recent contention that the Anavex sigma-1 receptor agonists can not only favorably modulate protein folding, thereby treating or preventing a number of central nervous system diseases, but also modulate proper chromatin functioning in genetic expression is immense. Genetic expression is the working of genes, the DNA segments, to ultimately cause biochemical outcomes. It's a complicated process, open to all sorts of problems. Genetic expression must be perfect, or very untoward things happen. Genetic diseases. Chromatin has to precisely operate in the process.
Presently, I can find no actual studies demonstrating that any of the Anavex sigma-1 receptors accomplishing this. I don't, however, question the matter. It will be very interesting to see such information emerge. I'm familiar with how the Anavex molecules can be used, tested for anti-aging outcomes, in various test species (such as the roundworm Ceanorhabditis elegans). But for chromatin studies, any number of organisms, from unicellular protozoans on up to various invertebrates might be test subjects.
Anyone know which organisms might be used to both test and demonstrate this phenomenon? Better, are there any existing chromatin studies involving the Anavex molecules?
If oral administration of blarcamesine, or Anavex 3-71 (at its far more minute dosage concentrations) might comprehensively direct precise gene expression, the applications will be far greater than anything currently envisioned.
Dosing might begin prenatally, before birth, to prevent genetic diseases that result from anomalous gene expression. Rett syndrome might be one of those. There could be hundreds more. All sorts of epigenetic applications.
There very likely would be gigantic applications in animal husbandry, promoting full and favorable gene expression in farm animals.
I'd also like to learn if blarcamesine or Anavex 3-71 (the later, in particular) might, in its low concentrations, facilitate precise genetic transfer in meiosis, the production of functioning, haploid eggs and sperm cells. Could Anavex 3-71 facilitate accurate transfer of genes from the parent on into his or her gametes (sperms and eggs) so as to reduce or prevent genetic errors?
Anavex, please, get some molecular biology grad students to investigate all of this, to get some preliminary indications of applications. If any are positive, the eventual Anavex story will be even larger, significantly changing medicine and human (and animal?) health in the future.
It seems that we are with the Anavex chromatin factor about where we were with the exact mechanism of action (MOA) of blarcamesine five or six years ago — back then very hazy. No longer. May the Anavex chromatin MOA soon come to clarity.
For we biologists, all so exciting. Profound new stuff. None of it in the textbooks yet. Someday....
Recent AVXL News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/12/2025 02:06:26 PM
- Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/12/2025 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025 • GlobeNewswire Inc. • 02/05/2025 12:30:00 PM
- Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio • GlobeNewswire Inc. • 01/27/2025 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2025 02:12:55 AM
- Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease • GlobeNewswire Inc. • 01/15/2025 12:30:00 PM
- New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients • GlobeNewswire Inc. • 01/13/2025 12:30:00 PM
- Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/06/2025 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/24/2024 12:00:31 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 12/23/2024 09:30:33 PM
- Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 12/23/2024 12:30:00 PM
- Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer’s Disease • GlobeNewswire Inc. • 12/23/2024 12:00:00 PM
- Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024 • GlobeNewswire Inc. • 12/16/2024 12:30:00 PM
- Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer’s Disease Data at J.P. Morgan 2025 Healthcare Conference • GlobeNewswire Inc. • 12/09/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/07/2024 02:00:08 AM
- Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024 • GlobeNewswire Inc. • 12/02/2024 12:30:00 PM
- Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer’s Disease to EMA • GlobeNewswire Inc. • 11/26/2024 12:30:00 PM
- Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer’s Disease Journal • GlobeNewswire Inc. • 11/25/2024 12:30:00 PM
- Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024 • GlobeNewswire Inc. • 10/31/2024 08:00:00 AM
- ZenaTech, Inc. (NASDAQ: ZENA) Software Company Acquisition • InvestorsHub NewsWire • 10/23/2024 12:03:31 PM
- Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia • GlobeNewswire Inc. • 10/17/2024 11:30:00 AM
- ZenaTech, Inc. (NASDAQ: ZENA) First US Trial of IQ Nano Drone for Inventory Management • InvestorsHub NewsWire • 10/15/2024 12:21:48 PM
- ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • InvestorsHub NewsWire • 10/01/2024 11:00:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
COEPTIS Announces the Launch of COEP Venture Group to Invest in AI, RPA, and AI Agent Startups • COEP • Feb 13, 2025 9:10 AM
Unitronix Corp. to Report Over 300% Gains in Cryptocurrency Assets • UTRX • Feb 13, 2025 7:15 AM
Hivello Token ($HVLO) now Live • MATE • Feb 11, 2025 9:27 AM
Animoca Brands leads Hivello funding round ahead of Token Listing • MATEF • Feb 10, 2025 10:20 AM
51 Labs Expands Sports Nutrition Line with Five New Innovative Products, Company in final phase of name and ticker symbol change • CAFI • Feb 10, 2025 9:00 AM
UAV Corp. Expanding in the Global UAV Market, Projected to Exceed $58 Billion by 2027, with Increasing Government and Commercial Sector Adoption • UMAV • Feb 6, 2025 8:30 AM